Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference

WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary cancer immunotherapy products, announced that preclinical data using the Company's novel drug product, INT230-6, was selected for a poster presentation at the National Cancer Institute’s annual Cancer Immunology and Immunotherapy Meeting. The conference is October 9 -10, 2014 in the Masur Auditorium at the National Institute of Health’s Clinical Center in Bethesda, Maryland. The poster is co-authored by Lewis H. Bender President & CEO of Intensity Therapeutics, Jay A. Berzofsky M.D., Ph.D., Chief of the Vaccine Branch Center for Cancer Research at the NCI and Masaki Terabe, Ph.D. Associate Scientist also at the NCI’s Vaccine Branch.

The poster’s title is: Novel cell penetrating formulation of cytotoxic agents administered intratumorally causes complete regression of large tumors and stimulation of an adaptive immune response in BALB/c syngeneic mice inoculated subcutaneously with murine CT26 colon cancer.

  • INT230-6 treatment resulted in substantial improvement in survival
  • Responders appear to be protected from recurrence of cancer

The poster will be available for viewing from 7:30AM EDT on Thursday, October 9, 2014, until 5:00 PM Friday October 10. The poster will also be available on the Technology page of Company's website.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with solid tumor cancers. Intensity Therapeutics is pioneering a new immunotherapy approach to treat cancer referred to as in situ chemovaccination. The Company’s products consist of proprietary formulations of proven chemotherapy drugs. These products, when injected directly into tumors result in significantly greater tumor growth inhibition and increased survival compared to conventionally delivered chemotherapy. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer to attack untreated tumors and prevent disease recurrence. Further information can be found at

Forward-Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.

Media & Investors:
Intensity Therapeutics, Inc.
Lewis Bender, 203-682-2434
President & CEO

Source: Intensity Therapeutics, Inc.